Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIND Study: Nicotine Transdermal Patch for Mild Cognitive Impairment
NCT02720445Phase 2Completed
- Sponsor
- University of Southern California
- Start
- Feb 2017
- Primary completion
- Aug 2025
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Mild Cognitive Impairment (MCI) comparing Nicotine Transdermal Patch with Placebo Patch (2 arms). Primary endpoint: Cogstate Battery International Shopping List Test - Total Immediate Recall at 24 months. Started Feb 2017; status: completed.
02
Drugs
nicotine patch
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT02720445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02720445.